New Mexico Cancer Research Alliance
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New Mexico Cancer Research Alliance sits in the top decile of US sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count).
New Mexico Cancer Research Alliance: 66 sponsored US clinical trials, 4 recruiting.
New Mexico Cancer Research Alliance sponsors 66 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 34 completed. 3 of these trials are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ovarian Cancer, with 4 trials.
Top-decile sponsor footprint
New Mexico Cancer Research Alliance ranks in the top decile of sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
34 of 59 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
66 total, page 2 of 2
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
NCT00391586
Expanded Breast Cancer Registry and Tissue Repository
NCT00322894
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
NCT00322634
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
NCT00276055
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
NCT00250822
Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions
NCT00250757
Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma
NCT00322855
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
NCT00250835
Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
NCT00250744
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
NCT00250718
Clinical Benefit of Topoisomerase Downregulation
NCT00250094
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
NCT00250029
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
NCT00250042
Combination Paclitaxel, Carboplatin and Temozolomide
NCT00249964
A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes
NCT00277043
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
NCT00277017
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 17 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the New Mexico Cancer Research Alliance pipeline
4 recruiting of 66 indexed (6% open); 34 completed (52%).
Phase mix: 3 late (III/IV) vs 34 early (I/II) (early-phase heavy).
Top condition: Ovarian Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New Mexico Cancer Research Alliance: open-pipeline peers nationwide
Peers matched on 66 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
New Mexico Cancer Research Alliance sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 66 trials (± recruiting share)
- Alkermes · 66 trials · 9% recruiting
- Cornell University · 66 trials · 15% recruiting
- University of Kansas · 66 trials · 8% recruiting
- Prisma Health-Upstate · 67 trials · 9% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Tufts University · 6% recruiting · 163 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this New Mexico Cancer Research Alliance page
66 registered trials is a research-attention snapshot, not an endorsement of New Mexico Cancer Research Alliance or any single study.
- 4 of New Mexico Cancer Research Alliance's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ovarian Cancer is the condition New Mexico Cancer Research Alliance studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ovarian Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
New Mexico Cancer Research Alliance pipeline card: 66 registered trials from official public datasets.Report a data error.